Indivior (LON:INDV) Receives “Buy” Rating from Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reissued their buy rating on shares of Indivior (LON:INDV) in a research report report published on Thursday, MarketBeat reports. They currently have a GBX 1,500 ($19.72) price target on the specialty pharmaceutical company’s stock.

Indivior Trading Down 14.6 %

LON INDV opened at GBX 777.46 ($10.22) on Thursday. The company has a market capitalization of £1.02 billion, a PE ratio of -1,010.13, a P/E/G ratio of -5.57 and a beta of 0.17. The company has a fifty day moving average of GBX 958.72 and a 200 day moving average of GBX 1,311.68. Indivior has a 1 year low of GBX 653 ($8.59) and a 1 year high of GBX 1,877.20 ($24.68). The company has a debt-to-equity ratio of 2,790.00, a current ratio of 0.85 and a quick ratio of 1.52.

Insider Buying and Selling at Indivior

In other news, insider Jo Le Couilliard acquired 1,490 shares of the business’s stock in a transaction on Friday, July 26th. The stock was bought at an average price of GBX 1,006 ($13.23) per share, with a total value of £14,989.40 ($19,709.93). 3.36% of the stock is owned by corporate insiders.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.